Literature DB >> 26813506

[Treatment for CKD-MBD(Chronic Kidney Disease-Mineral and Bone Disorder)].

Yuko Iwashita1, Yu Iwashita1, Takafumi Ito2, Takashi Shigematsu1.   

Abstract

CKD is a common disease that is estimated to develop one in eight persons in Japan. The CKD itself is highly risk factor on the cardiac/vascular mortality. In addition,a new concept has been proposed "CKD-MBD". CKD-MBD is composed of a combination of abnormal mineral metabolism, abnormal bone, and extra skeletal calcification with cardiovascular high mortality. Treatment for CKD-MBD is a wide-ranging. We aim to decline cardiovascular event, fracture, and mortality rate of patients with CKD. The main therapeutic target for CKD-MBD becomes the phosphate control. Today, we can use of the VRDA, Calcimimetics and muti-phosphate binders as a lot of pharmacological intervention.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26813506     DOI: CliCa1602259267

Source DB:  PubMed          Journal:  Clin Calcium        ISSN: 0917-5857


  1 in total

1.  Klotho preservation via histone deacetylase inhibition attenuates chronic kidney disease-associated bone injury in mice.

Authors:  Wenjun Lin; Yanning Li; Fang Chen; Shasha Yin; Zhihong Liu; Wangsen Cao
Journal:  Sci Rep       Date:  2017-04-07       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.